2126.HK实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 16:08):

Stats
今日成交量	844 000
平均成交量	299 391
市值	683.95M
EPS	HKD0 ( 2024-04-24 )
Last Dividend	HKD0 ( N/A )
Next Dividend	HKD0 ( N/A )
P/E	-0.840
ATR14	HKD0.0100 (0.58%)

音量相关性

長: -0.15 (neutral)

短: -0.50 (neutral)

Signal:(46.733) Neutral

JW THERAP-B 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

JW THERAP-B 相关性 - 货币/商品

0.48
( neutral )

0.53
( weak )

0.00
( neutral )

-0.51
( weak negative )

-0.52
( weak negative )

JW THERAP-B 财务报表

Annual	2023
营收:	HKD173.86M
毛利润:	HKD88.22M (50.74 %)
EPS:	HKD-1.870

FY	2023
营收:	HKD173.86M
毛利润:	HKD88.22M (50.74 %)
EPS:	HKD-1.870

FY	2022
营收:	HKD145.70M
毛利润:	HKD58.76M (40.33 %)
EPS:	HKD-2.06

FY	2021
营收:	HKD30.80M
毛利润:	HKD9.05M (29.37 %)
EPS:	HKD-5.32

Financial Reports:

No articles found.

JW THERAP-B

JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, focuses on developing, manufacturing, and commercializing cell-based immunotherapies for hematological cancers and solid tumors. The company offers cell-based immunotherapies, including CAR-T treatments, which is a treatment method that uses human immune cells to fight cancer. Its lead product candidate is Carteyva (relmacabtagene autoleucel), an anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of a range of hematological cancers. The company's pipeline products include JWCAR129, an autologous CAR-T therapy for the treatment of multiple myeloma; JWATM204, a TCR T-cell therapy candidate for the treatment of HCC; and JWATM203, an autologous T-cell receptor mimic T-cell therapy targeting alpha-fetoprotein for the treatment of hepatocellular carcinoma. JW (Cayman) Therapeutics Co. Ltd was founded in 2016 and is headquartered in Shanghai, the People's Republic of China.